title: The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins.
abstract: BACKGROUND
  The recently discovered apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately fourfold increase in serum triglycerides, whereas a knock-in model with human ApoA5 produced 50-70% lower concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor-alpha agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Despite these compelling molecular biology data, relatively little is known about ApoA5 protein in human serum.
  
  
  METHODS
  To better understand circulating concentrations and lipoprotein particle distribution of ApoA5, we expressed the recombinant human ApoA5 protein and raised antibodies against both the NH(2) and COOH termini.
  
  
  RESULTS
  Using the above reagents, we demonstrate for the first time that ApoA5 is present in human serum, although at much lower concentrations than other apolipoproteins such as ApoA1. Using a dual-antibody sandwich ELISA that we developed, we observed ApoA5 concentrations in human serum ranging from 24 to 406 microg/L compared with approximately 1 g/L for ApoA1. We also examined the lipoprotein particle distribution of ApoA5 and found that ApoA5 was detectable in VLDL, HDL, and chylomicrons, but not LDL.
  
  
  CONCLUSIONS
  These data demonstrate for the first time that ApoA5 is a secreted protein present in human serum and is associated with specific lipoprotein particles. In addition, our data indicate that the circulating concentration of human ApoA5 is very low compared with other apolipoproteins.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
authors.forename: Peter J
authors.initials: PJ
authors.lastname: O'Brien
authors.forename: William E
authors.initials: WE
authors.lastname: Alborn
authors.forename: John H
authors.initials: JH
authors.lastname: Sloan
authors.forename: Maverick
authors.initials: M
authors.lastname: Ulmer
authors.forename: Amechand
authors.initials: A
authors.lastname: Boodhoo
authors.forename: Michael D
authors.initials: MD
authors.lastname: Knierman
authors.forename: Albert E
authors.initials: AE
authors.lastname: Schultze
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Konrad
mesh_terms: D000072040:Apolipoprotein A-V; D001053:Apolipoproteins / Q000097:blood*; D001054:Apolipoproteins A; D015153:Blotting, Western; D002914:Chylomicrons / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D047468:Immunoprecipitation; D008075:Lipoproteins, HDL / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood; D012016:Reference Values
chemical_list: C437704:APOA5 protein, human; D000072040:Apolipoprotein A-V; D001053:Apolipoproteins; D001054:Apolipoproteins A; D002914:Chylomicrons; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL